资料显示，云南贝泰妮生物科技集团股份有限公司位于云南省昆明市高新区科医路53号，成立日期2010 年5月13日，上市日期2021年3月25日，公司主营业务涉及公司是以"薇诺娜"品牌为核心,专注于应用纯 天然的植物活性成分提供温和、专业的皮肤护理产品,重点针对敏感性肌肤,在产品销售渠道上与互联网 深度融合的专业化妆品生产企业。主营业务收入构成为：护肤品84.36%，彩妆10.07%，医疗器械 4.88%，服务及其他0.70%。 截至11月10日，贝泰妮股东户数3.97万，较上期增加3.94%；人均流通股10681股，较上期减少3.79%。 2025年1月-9月，贝泰妮实现营业收入34.64亿元，同比减少13.78%；归母净利润2.72亿元，同比减少 34.45%。 分红方面，贝泰妮A股上市后累计派现12.89亿元。近三年，累计派现8.44亿元。 11月21日，贝泰妮跌1.95%，成交额2.29亿元。两融数据显示，当日贝泰妮获融资买入额1644.08万元， 融资偿还3139.94万元，融资净买入-1495.85万元。截至11月21日，贝泰妮融资融券余额合计6.63亿元。 融资方面，贝泰妮当日融资买入1644.08 ...

11月20日，贝泰妮盘中下跌2.02%，截至10:27，报42.74元/股，成交1.24亿元，换手率0.68%，总市值 181.05亿元。 资金流向方面，主力资金净流出1591.54万元，特大单买入1197.98万元，占比9.69%，卖出1888.49万 元，占比15.27%；大单买入2612.40万元，占比21.12%，卖出3513.43万元，占比28.41%。 贝泰妮今年以来股价涨1.54%，近5个交易日跌1.16%，近20日跌6.31%，近60日跌8.30%。 贝泰妮所属申万行业为：美容护理-化妆品-品牌化妆品。所属概念板块包括：化妆品、人工智能、出海 概念、医疗器械、融资融券等。 截至11月10日，贝泰妮股东户数3.97万，较上期增加3.94%；人均流通股10681股，较上期减少3.79%。 2025年1月-9月，贝泰妮实现营业收入34.64亿元，同比减少13.78%；归母净利润2.72亿元，同比减少 34.45%。 分红方面，贝泰妮A股上市后累计派现12.89亿元。近三年，累计派现8.44亿元。 机构持仓方面，截止2025年9月30日，贝泰妮十大流通股东中，香港中央结算有限公司位居第六大流通 股东， ...

Core Insights - The Chinese beauty industry is at a critical juncture, transitioning from rapid growth driven by channels and traffic to a focus on brand value and operational excellence [1] - Recent financial reports from leading domestic beauty companies reveal a divide: some are struggling with transformation pains, while others are rebounding due to strong brand value [1] Group 1: Performance Challenges - Beitaini reported a revenue of 3.464 billion yuan for the first three quarters of 2025, a year-on-year decline of 13.78%, with a net profit of 272 million yuan, down 34.45% [2] - In Q3, Beitaini's revenue was 1.092 billion yuan, a decline of 9.95%, but net profit increased by 136.55% to 25.22 million yuan due to cost-cutting and a shift to high-quality growth [3] - Beitaini's operating costs decreased by 15.75% to 889 million yuan, while sales expenses were 1.838 billion yuan, down 8.55% [6] - Furuida's revenue for the first three quarters was 2.597 billion yuan, down 7.34%, with a net profit of 142 million yuan, a decrease of 17.19% [7] - The brand Yailabo's revenue fell by 28.93% in Q3, indicating a significant decline from its peak performance in 2023 [11] Group 2: Successful Turnarounds - Shanghai Jahwa achieved a revenue of 4.961 billion yuan in the first three quarters of 2025, a 10.8% increase, with net profit soaring by 149.1% to 405 million yuan [12] - The company reported a Q3 revenue of 1.482 billion yuan, up 28.3%, reversing a previous decline [12] - The turnaround is attributed to a strategic focus on core brands and effective brand activation under new CEO Lin Xiaohai, emphasizing brand value as a growth strategy [15][18] Group 3: Industry Trends - The beauty industry is shifting towards a focus on brand value and ecosystem building, moving away from reliance on external factors like channels and marketing [19][23] - New brands face challenges due to the fragmentation of channels and rising costs, leading to a need for deeper brand connections with consumers [19][21] - Established brands like Shanghai Jahwa demonstrate resilience through strong brand recognition and emotional connections with consumers, allowing for rapid recovery when strategic adjustments are made [22] - The industry must prioritize building a multi-brand ecosystem and sustainable financial practices, as seen in Beitaini's recent focus on profitability [24]

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Insights - The company is experiencing a steady recovery in growth momentum through channel optimization and product focus, with a 13.78% year-on-year decline in revenue for the first three quarters of 2025, totaling 3.464 billion yuan [1][4] - The third quarter revenue reached 1.092 billion yuan, showing a reduced decline of 9.95% compared to the previous quarter, indicating initial effectiveness of channel and product adjustments [1] - Key initiatives contributing to revenue improvement include the simplification of SKU and reduced promotions on low-margin products, alongside enhanced online channel operations [1] - The main brand, Winona, has shown stable performance, particularly during the Double Eleven pre-sale period, while the high-end anti-aging brand, Aikeman, has seen strong growth [1] Summary by Sections Revenue and Growth - The company achieved a total revenue of 3.464 billion yuan in the first three quarters of 2025, down 13.78% year-on-year, with a third-quarter revenue of 1.092 billion yuan, down 9.95% [1][3] - The revenue decline is narrowing, suggesting that operational adjustments are beginning to yield results [1] Profitability - The gross margin for Q3 2025 was 70.68%, a decrease of 5.67 percentage points year-on-year [2] - The net profit margin improved to 2.52%, indicating a significant enhancement in profitability compared to the same period last year [2] Future Outlook - The company is expected to continue its operational adjustments, with the performance during the Double Eleven sales event being a critical indicator of the effectiveness of its strategies [2] - The multi-brand matrix, anchored by Winona and supported by Aikeman and the newly introduced TriPollar brand, is anticipated to create a second growth curve [2] - EPS forecasts for 2025, 2026, and 2027 are projected at 1.02, 1.22, and 1.43 yuan respectively [2][3]

Core Viewpoint - The article discusses the recent investment by Betaini, a publicly listed company, in the Jin Yu Fund, highlighting the strategic move to seek new growth opportunities in the healthcare sector amidst declining market performance [5][9][10]. Investment Details - Betaini has committed 50 million yuan to the Jin Yu Fund, which has a total subscription amount of 1 billion yuan and a partnership duration of 10 years [7][9]. - The Jin Yu Fund is managed by Jin Yu Mao Wu, a venture capital firm based in Jiangsu, focusing on strategic emerging industries such as new materials, renewable energy, and healthcare [7][9]. - The largest limited partner (LP) in the fund is the Jiangsu Wuxi Biomedical Industry Special Mother Fund, contributing 300 million yuan, accounting for 30% of the fund [7][8]. Company Background - Betaini is known for its skincare brand Winona, which has gained significant market share in the sensitive skin segment, previously exceeding a market capitalization of 120 billion yuan but has now fallen below 20 billion yuan [9][10]. - The company is facing intense competition in the cosmetics market, leading to a 49.01% decline in net profit in the first half of the year [10]. Strategic Rationale - The investment in the Jin Yu Fund is part of Betaini's strategy to deepen collaboration with professional funds and enhance its presence in the health ecosystem, aiming to improve its overall competitiveness and profitability [10][12]. - This is not Betaini's first investment with Jin Yu Mao Wu; the company previously invested 30 million yuan in another fund managed by the same firm, indicating a pattern of strategic partnerships [12]. Industry Context - The trend of companies becoming LPs in venture capital funds is becoming more common, as firms seek to leverage established relationships and trust with previous investors [13]. - The current investment landscape shows a scarcity of willing social capital, making corporate LPs a vital resource in the market [13].

Investment Rating - The investment rating for the company is "Accumulate" (Maintain) [5] Core Views - The company reported a year-on-year increase of 137% in net profit attributable to shareholders for Q3 2025 [5] - The main brand, Winona, continues to lead the domestic dermatological skincare market, with significant competitive advantages [7] - The company has improved its gross margin to 74.3% in Q1-Q3 2025, focusing on brand building and core product optimization [7] - The forecasted net profit for 2025-2027 is expected to be 449 million, 557 million, and 673 million RMB respectively, with corresponding year-on-year changes of -10.84%, +24%, and +20.97% [6][7] Financial Summary - The company's total revenue for 2023 is projected at 5,522 million RMB, with a year-on-year growth rate of 10.14% [6] - The net profit for 2023 is estimated at 757 million RMB, reflecting a year-on-year decrease of 28.01% [6] - The earnings per share (EPS) for 2025 is projected to be 1.06 RMB, with a price-to-earnings (P/E) ratio of 42.07 [6][9] - The company’s total market capitalization is approximately 18,867.14 million RMB [3]

Group 1: Strategic Adjustments - The company has introduced new talent in key online and mid-platform positions, focusing on core products and optimizing business structure to enhance product competitiveness and channel penetration [1] - Systematic improvements in profitability, technological accumulation, and brand layout have been achieved through ongoing strategic adjustments [1] Group 2: Research and Development - R&D expenses decreased by 14.17% year-on-year, attributed to normal fluctuations in project progress, with a commitment to maintaining high levels of R&D investment [1] - The company is leveraging its Yunnan Province plant extraction laboratory and global R&D centers to conduct comprehensive research projects from basic research to product development [2] Group 3: Financial Performance - Operating cash flow reached 442 million yuan in the first three quarters, a remarkable increase of 6772.14%, indicating strong cash generation capability and operational efficiency [2] - The company has implemented proactive inventory and channel management strategies, laying a solid foundation for long-term value growth [2] Group 4: Intangible Assets - Intangible assets increased significantly by 116%, primarily due to the acquisition of trademarks, patents, and non-patent technologies related to the TriPollar brand [2] - The acquisition strengthens the company's R&D and technological moat, marking its entry into the billion-level beauty instrument market and opening a second growth line [2]

Core Viewpoint - Beitaini is experiencing significant operational challenges, reflected in its declining revenue and net profit for the first three quarters, despite a slight recovery in the third quarter [1][4][10] Financial Performance - For the first three quarters, Beitaini reported revenue of 3.464 billion yuan, a year-on-year decrease of 13.78%, and a net profit of 272 million yuan, down 34.45% year-on-year [1][4] - In the third quarter alone, the company achieved a net profit of 25.22 million yuan, marking a return to profitability, but this does not offset the overall performance decline [1][4] Market Position and Valuation - Beitaini's market capitalization has dropped significantly from over 120 billion yuan at its peak to approximately 19 billion yuan, indicating a loss of over 100 billion yuan in market value since its IPO [2][4] - The stock price has fallen below its initial offering price, reflecting investor concerns about the company's growth prospects [2] Revenue Channels - All three major revenue channels (online, OMO, and offline) have shown declines, with offline sales plummeting by 41.6% [6] - Specific declines in major e-commerce platforms include a 10.5% drop in Alibaba, 22.1% in JD.com, and 18.9% in Vipshop, while Douyin was the only platform to show a 7.4% increase [6] Product Performance - The core product categories, skincare and cosmetics, saw revenue declines of 12.0% and 7.1%, respectively, with skincare accounting for 85% of total revenue [6][7] - The primary brand, Winona, generated 1.95 billion yuan in revenue for the first half of 2025, representing 82.17% of total revenue, but its growth has slowed significantly [7] Strategic Initiatives - To mitigate reliance on its main brand, Beitaini is diversifying its product offerings, including launching new brands and acquiring existing ones [7] - However, the development of new brands requires substantial investment and may take time to yield results, leading to revised profit forecasts for 2025-2027 [7][9] Profitability Challenges - Despite a slight increase in gross margin to 74.3%, the company's expense ratio has risen to 67.7%, with sales expenses reaching a record high of 53.1%, squeezing profit margins [10][12] - The sales expense ratio has increased significantly over the years, indicating that a large portion of revenue is being consumed by marketing without driving growth [12]

Core Viewpoint - After returning to profitability in the third quarter, Betaini announced a share reduction by its second-largest shareholder, Sequoia Capital, which sold 8.43 million shares, accounting for 2% of the total share capital, raising 368 million yuan [1][2][3] Shareholder Actions - Sequoia Capital's share reduction was executed through a block trade, reducing its holding to 7.66% [2] - Since the lifting of the share lock-up in 2022, Sequoia has completed five rounds of reductions, cashing out nearly 6 billion yuan [2][4] - Other shareholders, including the controlling family of the actual controller, have also been reducing their stakes, indicating a broader trend of capital exit [4][5] Financial Performance - In Q3, Betaini reported a net profit of 252 million yuan, a year-on-year increase of 136.55%, but this was largely driven by investment income rather than core business improvement [3][8] - For the first three quarters, the company experienced a revenue decline of 13.78% to 3.464 billion yuan and a net profit drop of 34.45% to 272 million yuan, marking the first time in six years that both revenue and net profit declined [8][6] Market Challenges - The company's reliance on e-commerce and key opinion leaders (KOLs) for sales has become unsustainable, leading to a decline in profitability [3][11] - Betaini's core brand, Winona, contributed 82.17% of revenue in the first half of 2025, facing increasing competition and declining growth rates [17][18] Strategic Adjustments - The company is focusing on optimizing its multi-channel strategy and expanding its overseas business, particularly in Thailand and other international markets [12][16] - Betaini has implemented cost-cutting measures, reducing sales and management expenses while maintaining a stable R&D investment rate [13][15] Future Outlook - Investors are closely monitoring Betaini's ability to diversify its brand portfolio and reduce dependence on Winona to establish sustainable growth [18]

Report Summary 1. Report Industry Investment Rating - No information provided. 2. Core Viewpoints - Since 2024, the pharmaceutical reform policy has been continuously explored, leading to stagnant growth in industry revenue and downward pressure on profits. The company's revenue has basically stabilized compared to the same period last year, with a 2.77% year - on - year decline in the first nine months of 2025. The company is committed to transformation, focusing on the main business, and strengthening its advantages in non - medical insurance - dependent category diversification and omni - channel marketing [24]. 3. Summary by Relevant Catalogs 3.1 Research Basic Situation - The research object is Jianzhijia, belonging to the pharmaceutical business industry. The reception time was on October 30, 2025. The listed company's reception staff included the chairman, general manager Lan Bo, the chief financial officer and board secretary Li Heng, and independent director Guan Yunhong [17]. 3.2 Detailed Research Institutions - The reception objects included investors and others [20]. 3.3 Research Institution Proportion - No information provided. 3.4 Main Content Data - **Revenue Situation**: From 2022 - 2024, the proportion of medical insurance settlement income based on personal accounts in the company's pharmacy main business income (excluding B2C) was 52%, 47%, and 44% respectively, dropping to 40% from January to September 2025. In the first nine months of 2025, the company achieved an operating income of 6.549 billion yuan, a 2.77% year - on - year decrease. The online operating income was 1.9794442 billion yuan, a 9.71% year - on - year increase, accounting for 30.23% of the operating income. The company strengthened cost control, with a 2.84% year - on - year decrease in period costs [24]. - **Business Expansion Plan**: The company focuses on the main business, continues to strengthen its advantages in non - medical insurance - dependent category diversification and omni - channel marketing. It will build more specialty pharmacies for diabetes, cardiovascular and cerebrovascular diseases, etc., and develop specialized solutions for single diseases. It will also strengthen the cooperation with leading enterprises in personal care products and develop exclusive products [25][26]. - **Measures to Deal with the Weak Growth of the Pharmaceutical Retail Market**: The company focuses on transformation, stability of revenue, and cost - control and efficiency - improvement. It promotes business transformation, improves the efficiency of existing stores, complies with regulations, controls costs, and adjusts category planning to support transformation and enhance supply chain capabilities [27].